![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
![Publish Open Access Finland]({"type":"image" , "src" : "/sda/110396/JournalAd-OA-Agreements.gif"})
![Electronic Banner Advert for Current Medical Research and Opinion]({"type":"image" , "src" : "/sda/111144/JournalAd-Announce-ICMO-LM.jpg"})
Abstract
A novel combination consisting of the neprilysin inhibitor, sacubitril, and the angiotensin-receptor blocker, valsartan (belonging to the newly established class of angiotensin receptor/neprilysin inhibitors), was shown to be effective in the treatment of heart failure (HF) by improving patient clinical status, and reducing re-hospitalization rate and mortality. We report a case of a 29 year old male with HF, dilated cardiomyopathy possibly related to myocarditis and atrial fibrillation with reduced ejection fraction. Sacubitril/valsartan treatment was initiated after two years of standard treatment. In two years, therapy with sacubitril/valsartan led to persistence in sinus rhythm, progressive recovery of ejection fraction, functionality and reduction of cardiac volumes. The patient is currently in good condition and has suspended diuretic therapy in the last six months.
Acknowledgements
Editorial assistance was provided by Luisa Granziero PhD and Luca Giacomelli PhD on behalf of Content Ed Net (Rome, Italy). This assistance was supported by Novartis Farma (Origgio, Italy).
Transparency
Declaration of funding
This manuscript forms part of a supplement that was funded by Novartis Farma (Origgio, Italy).
Declaration of financial/other relationships
No potential conflict of interest was reported by the authors. CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.